Skip to main content

Table 1 Overview of the current literature on mRNA-encoded antibodies

From: mRNA as novel technology for passive immunotherapy

Publication Pardi et al., 2017
Stadler et al., 2017
Thran et al., 2017
Sabnis et al., 2018
Capping (structure) Enzymatic (Cap1) Enzymatic (Cap1) Co-transcriptional (Cap0); Enzymatic (Cap1) Not disclosed (Cap1)
5′ UTR Tobacco etch virus Tobacco etch virus Hydroxysteroid (17-β) dehydrogenase 4 Unknown origin
3′ UTR Not disclosed F-I (not yet characterized) Human albumin Human alpha globin
Polyadenylation (structure) Vector-encoded (monopartite; approximately A100) Vector-encoded (bipartite; A30-linker-A70) Enzymatic adenylation (bipartite; A64-linker-PolyA) Poly(A) tail (details not disclosed)
Base modifications N1-methyl-pseudouridine N1-methyl-pseudouridine Unmodified N1-methyl-pseudouridine
Codon usage Not disclosed Sequence provided GC enrichment (disclosed in [218]) Not disclosed
mRNA purification FPLC HPLC HPLC Not disclosed
Formulation/delivery LNP/intravenous TransIT/intravenous LNP/intravenous LNP/intravenous
Dose (range) 1–1.4 mg/kg Approx. 0.25 mg/kga 0.06–2 mg/kg 0.3 mg/kg
Species M. musculus M. musculus M. musculus M. fascicularis
Maximum titer across experiments (range) 70–200 µg/ml 7 µg/ml 20–400 µg/ml 4 µg/ml
  1. aDue to lack of information, the value was calculated here for mice of 20 g in weight